Stereotaxis
    Print Page  Close Window
S-1/A
STEREOTAXIS, INC. filed this Form S-1/A on 06/17/2004
Entire Document
 << Previous Page | Next Page >>
Table of Contents

                         
Number of Percent Percent
shares beneficially beneficially
beneficially owned before owned after
owned this offering this offering



Directors and named executive officers
                       
Fred A. Middleton(5)
    11,869,935       16.34 %       %
Christopher Alafi(6)
    8,679,704       11.96 %       %
Gregory R. Johnson(7)
    5,213,225       7.21 %       %
David J. Parker(8)
    4,725,703       6.55 %       %
William C. Mills III(9)
    3,706,530       5.13 %       %
John C. Aplin(10)
    2,725,267       3.78 %       %
Randall D. Ledford(11)
    2,650,408       3.67 %       %
Bevil J. Hogg(12)
    1,997,708       2.74 %       %
Ralph G. Dacey, Jr.
    180,000         *       %
William M. Kelley(13)
    119,376         *       %
Michael P. Kaminski(14)
    284,373         *       %
Douglas M. Bruce(15)
    481,771         *       %
Melissa Walker(16)
    205,209         *       %
Abhijeet Lele(17)
    6,813,687       9.36 %       %
Nicola J.H. Young(18)
    421,875         *       %
All directors and executive officers as a group (16 persons)
    50,074,771       65.13 %       %


  * Indicates ownership of less than 1%.

(1)  Includes 116,480 shares of common stock and 2,695,306 shares of preferred stock held by Sanderling Venture Partners II, L.P., 43,629 shares of common stock and 1,042,194 shares of preferred stock held by Sanderling Management Limited, Custodian FBO The Investors of Sanderling Ventures Limited, 1,841,216 shares of preferred stock and 34,130 warrants held by Sanderling IV Biomedical Co-Investment Fund, L.P., 807,005 shares of preferred stock held by Sanderling Venture Partners IV Co-Investment Fund, L.P., 1,995,215 shares of preferred stock and 305,995 warrants held by Sanderling Venture Partners V Co-Investment Fund, L.P., 290,312 shares of preferred stock and 88,932 warrants held by Sanderling V Beteiligungs GmbH & Co. KG., 326,303 shares of preferred stock and 81,374 warrants held by Sanderling V Limited Partnership, 1,209,629 shares of preferred stock and 135,743 warrants held by Sanderling V Biomedical Co-Investment Fund, L.P., 76,667 shares of preferred stock and 11,301 warrants held by Sanderling Ventures Management V; 12,896 shares of common stock and 308,057 shares of preferred stock held by Sanderling Management Limited, Custodian FBO Middleton-McNeil, L.P.; and 1,728 warrants held by Sanderling II Limited Partnership (collectively, “Sanderling”).

  Middleton-McNeil Associates, L.P. is the general partner of Sanderling Venture Partners II, L.P. and has voting and dispositive authority over the shares owned by Sanderling Venture Partners II, L.P. Middleton-McNeil Associates, L.P. is managed by its general partners. Middleton-McNeil, L.P. is the general partner of Sanderling Ventures Limited, L.P. and Sanderling II Limited Partnership and has voting and dispositive authority over the shares owned by such entities. Middleton-McNeil, L.P. is managed by its general partners. Sanderling Management Limited, Custodian FBO the Investors of Sanderling Ventures Limited, and Sanderling Management Limited, Custodian FBO Middleton-McNeil, L.P., are managed by a board of directors. Middleton-McNeil Associates IV, LLC is the general partner of Sanderling IV Biomedical Co-Investment Fund, L.P. and has voting and dispositive authority over the shares owned by Sanderling IV Biomedical Co-Investment Fund, L.P. Middleton-McNeil Associates IV, LLC is managed by its members. Middleton-McNeil Associates IV, L.P. is the general partner of Sanderling Venture Partners IV Co-Investment Fund, L.P. and has voting and dispositive power

96


 << Previous Page | Next Page >>